Neurologists Report
Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, According to Spherix Global Insights Neurologist Survey
February 22, 2024 15:04 ET | Spherix Global Insights
EXTON, PA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The 2023 announcement of newly approved disease-modifying therapy (DMT) Leqembi (lecanemab) for Alzheimer’s Disease (AD) sparked eager anticipation...
Parkinson’s Disease
Parkinson’s Disease Patient Identification and Education Will Need to Improve When New Disease Modifying Therapies Are Approved, According to Spherix Global Insights
February 16, 2024 10:40 ET | Spherix Global Insights
EXTON, PA, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Millions of people worldwide are affected by Parkinson’s disease (PD), prompting the need for effective disease-modifying therapies (DMTs) to target this...
Stakes Are High for
Stakes Are High for Regeneron's Eylea HD as Genentech's Vabysmo Continues to Gain Momentum, Prompting Doctors to Weigh Their Options Between Two Industry Titans, According to Spherix Global Insights
February 08, 2024 15:17 ET | Spherix Global Insights
Exton, Pennsylvania, Feb. 08, 2024 (GLOBE NEWSWIRE) -- As Age-Related Macular Degeneration (AMD) Awareness Month unfolds, illuminating the visual challenges faced by millions of Americans with AMD,...
Changes Afoot for th
Changes Afoot for the Treatment of Psoriatic Arthritis with Marked Gains in Preference and Utilization of IL-17 Inhibitors
January 22, 2024 10:47 ET | Spherix Global Insights
EXTON, PA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Since the first US FDA-approved tumor necrosis factor (TNF) inhibitor in 2002 for the treatment of psoriatic arthritis (PsA), TNF’s have upheld their...
Spherix Global Insights + Cheeriodicals
Spherix Global Insights Delivers Cheeriodicals to Dialysis Patients
January 18, 2024 10:45 ET | Spherix Global Insights
Exton, PA, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Colleagues from Spherix Global Insights partnered with Cheeriodicals to assemble and deliver care packages to dialysis patients at local dialysis clinics...
Novartis' Cosentyx S
Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for Significant Future Adoption at the Expense of AbbVie's Humira
January 10, 2024 15:58 ET | Spherix Global Insights
Exton, Pennsylvania, Jan. 10, 2024 (GLOBE NEWSWIRE) -- In late October 2023, the FDA granted approval to Novartis' Cosentyx (secukinumab) for treating hidradenitis suppurativa (HS), marking it as...
Use of SGLT2 Inhibit
Use of SGLT2 Inhibitors Continues to Expand for the Treatment of Chronic Kidney Disease, with Eli Lilly/Boehringer Ingelheim’s Jardiance Making Significant Strides Following Label Expansion
January 03, 2024 16:13 ET | Spherix Global Insights
EXTON, PA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Since 2019, audited records of chronic kidney disease (CKD) non-dialysis patients has revealed an ongoing, annual uptick in the proportion of...
US Neurologists Opti
US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Halting Neurodegeneration as Leading Treatment Priority
January 03, 2024 09:46 ET | Spherix Global Insights
EXTON, PA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Huntington’s disease (HD) could be called the perfect storm of neurodegenerative diseases. It causes a loss of critical striatal neurons which affect not...
“I Need to See It Wi
“I Need to See It With My Own Eyes”: How US Ophthalmologists React to Apellis’ Syfovre Safety Warnings When Managing Geographic Atrophy
December 14, 2023 12:58 ET | Spherix Global Insights
Exton, PA, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Geographic Atrophy (GA), the most severe stage of dry age-related macular degeneration (dAMD), poses a significant challenge as retinal cells atrophy,...
U.S. Neurologists Ea
U.S. Neurologists Eagerly Await Promising Oral Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis Treatment Pipeline, Though Recent Trial Readouts Might Hamper Initial Excitement
December 13, 2023 14:03 ET | Spherix Global Insights
Exton, PA, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Several clinical trials are underway for Bruton’s tyrosine kinase inhibitors (BTKi) targeting relapsing and progressive multiple sclerosis (RMS/PPMS)....